Aidoc Collaborates with NVIDIA | Objective – to Establish Guidelines for AI Adoption In Healthcare

Aidoc, a pioneering force in clinical AI, today announced it is co-developing with NVIDIA a Blueprint for Resilient Integration and Deployment of Guided Excellence (BRIDGE), a guideline that aims to accelerate AI adoption across the healthcare industry.

Slated for release in early 2025, this industry-first guideline will offer a robust, evidence-driven framework for seamlessly integrating AI into clinical workflows, helping healthcare organizations scale AI innovation with greater speed and confidence. The guideline will help establish clear pathways for healthcare systems to fully harness the potential of AI in improving patient outcomes.

Despite the approval of over 900 FDA-cleared AI tools for medical imaging, healthcare systems remain mired in fragmentation, operational inefficiencies and scalability issues. The BRIDGE guideline will provide a comprehensive, vendor-neutral roadmap, helping address these persistent challenges and empowering providers to unlock AI’s full potential.

Breaking Barriers to AI Adoption

A key challenge for many AI solutions has been the failure to scale effectively because critical considerations around integration were not addressed early enough in the development process. The BRIDGE guideline will provide healthcare systems with direction on addressing scalability and interoperability from the start, enabling the implementation of AI solutions across multiple sites simultaneously.

“AI holds the potential to revolutionize patient care, but its progress has been stalled by fragmented systems and the inability to scale effectively,” said Demetri Giannikopoulos, Chief Transformation Officer, Aidoc. “The BRIDGE guideline will focus on breaking down these barriers, offering a powerful, evidence-based framework that health systems can rely on not just adopt AI but to help scale it across their operations. This will drive both operational efficiency and significantly better outcomes for patients and clinicians alike.”

While many existing guidelines focus on governance, regulatory concerns and responsible development practices. BRIDGE will be specifically designed to help developers and healthcare providers consider the practicalities of real-world deployment. This comprehensive framework will empower organizations to navigate the complexities of AI adoption, from ideation to implementation and scalability across hospital systems.

How the Guidelines Will Drive AI Adoption

This guideline will enable healthcare systems to adopt and scale AI faster and more effectively by simplifying the design, validation, deployment, and monitoring of AI tools.

Key areas of focus include:

  • Standardized Validation: Ensuring AI solutions are rigorously tested for real-world use.
  • Interoperability: Facilitating seamless integration of AI tools from different vendors.
  • Scalable Deployment: Providing a roadmap for efficient AI expansion across hospital systems.
  • Continuous Monitoring: Offering best practices to maintain AI accuracy post-deployment.

The BRIDGE guideline will lay the groundwork for aligning to industry frameworks, like MONAI, to build the blueprint for the medical AI enterprise platform. MONAI, co-founded by academia and industry, including NVIDIA, in 2019, provides the essential tools for medical AI development, validation, and deployment, and provides a strong foundation for building the BRIDGE guideline. With more than three million downloads and currently being used in FDA-approved software-as-medical-device applications, MONAI and its standardization, interoperability and scalability is key to transformative solutions in healthcare.

Real-World Impact

The guideline will be developed through close collaboration with healthcare providers, academic partners, and industry leaders. This effort will leverage the expertise and experience from real-world AI initiatives to help ensure the framework is practical, actionable, and scalable. By focusing on real-world challenges in AI integration, the guideline aims to provide a comprehensive and adaptable approach for healthcare organizations.

Learn more about the BRIDGE Guideline including how to access it in 2025 and help shape the overall direction here.

SourceAidoc

Hot this week

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.